Lyon,
France, July 26, 2007 Flamel Technologies
(NASDAQ:FLML) expects to release its financial results for the second quarter on Wednesday, August 1st after the market close.
To participate in the conference call, investors in the US and Canada are invited to dial 1-800-374-1498.
About Flamel Technologies
Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two
unique polymer-based delivery technologies for medical applications.
This document contains a number
of matters, particularly as related to the status of various research
projects and technology platforms, that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The document reflects the current
view of management with respect to future events and is subject
to risks and uncertainties that could cause actual results to
differ materially from those contemplated in such forward-looking
statements. These risks include risks that
products in the development stage may not achieve scientific objectives
or milestones or meet stringent regulatory requirements, uncertainties
regarding market acceptance of products in development, the impact
of competitive products and pricing, and the risks associated
with Flamel's reliance on outside parties and key strategic alliances.
For further information on
the Company, please review Flamel's Annual Report on the Securities
and Exchange Commission Form 20-F for the year ended December
31, 2006.
A conference call to discuss the results has been scheduled for Thursday, August 2nd at 8:30 AM (EDT).
A question and answer period is expected to follow the discussion of results.
International callers are invited to call 1-706-634-7261. The Conference ID number is: 11213762.
Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs;
it is the intellectual platform licensed by GlaxoSmithKline for the development of Coreg CR®.
Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides.